The idea of developing therapeutic vaccines against cancer has been explored since the early discovery of tumor-specific antigens by Georg Klein in 1967. However, challenges including weak immunogenicity, systematic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. The emerging field of biomaterials has led to advancements in many different biomedical applications, and it may also help cancer vaccines overcome the various aforementioned challenges. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (i.e. DNA, mRNA, peptide/protein, cell-based), along with novel biomaterial-based delivery platforms that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.